Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
المؤلفون المشاركون
Patel, Jesal C.
Maughan, Benjamin L.
Batten, Julia A.
Zhang, Tian Y.
Agarwal, Archana M.
Agarwal, Neeraj
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-05-08
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer.
However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease.
Over the last decade, it has been recognized that despite the failure of ADT, most prostate cancers maintain some dependence on androgen and/or androgen receptor (AR) signaling for proliferation.
Furthermore, androgen independent molecular pathways have been identified as drivers of continued progression of CRPC.
Subsequently, drugs have been developed targeting these pathways, many of which have received regulatory approval.
Agents such as abiraterone, enzalutamide, orteronel (TAK-700), and ARN-509 target androgen signaling.
Sipuleucel-T, ipilimumab, and tasquinimod augment immune-mediated tumor killing.
Agents targeting classic tumorogenesis pathways including vascular endothelial growth factor, hepatocyte growth factor, insulin like growth factor-1, tumor suppressor, and those which regulate apoptosis and cell cycles are currently being developed.
This paper aims to focus on emerging molecular pathways underlying progression of CRPC, and the drugs targeting these pathways, which have recently been approved or have reached advanced stages of development in either phase II or phase III clinical trials.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Patel, Jesal C.& Maughan, Benjamin L.& Agarwal, Archana M.& Batten, Julia A.& Zhang, Tian Y.& Agarwal, Neeraj. 2013. Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. Prostate Cancer،Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-513327
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Patel, Jesal C.…[et al.]. Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. Prostate Cancer No. 2013 (2013), pp.1-12.
https://search.emarefa.net/detail/BIM-513327
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Patel, Jesal C.& Maughan, Benjamin L.& Agarwal, Archana M.& Batten, Julia A.& Zhang, Tian Y.& Agarwal, Neeraj. Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. Prostate Cancer. 2013. Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-513327
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-513327
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر